南京医药
(600713)
| 流通市值：67.59亿 | | | 总市值：68.55亿 |
| 流通股本：12.90亿 | | | 总股本：13.08亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 41,686,951,461.27 | 27,822,576,569.95 | 13,843,779,763.6 | 54,963,277,449.95 |
| 营业总成本 | 40,821,636,986.2 | 27,234,806,874.98 | 13,504,978,803.17 | 53,921,722,737.41 |
| 其他经营收益 | | | | |
| 营业利润 | 771,158,228.29 | 526,511,321.54 | 284,681,693.04 | 1,160,106,280.91 |
| 利润总额 | 760,218,497.21 | 523,341,758.24 | 281,917,557.9 | 1,157,627,933.72 |
| 净利润 | 544,841,352.38 | 378,501,024.19 | 211,697,444.59 | 832,668,876.52 |
| 每股收益 | | | | |
| 其他综合收益 | -24,521,011.89 | -19,006,250.54 | -13,095,362.19 | -10,643,046.56 |
| 综合收益总额 | 520,320,340.49 | 359,494,773.65 | 198,602,082.4 | 822,025,829.96 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 34,974,238,801.53 | 33,249,155,558.99 | 32,465,200,997.55 | 28,411,741,404.44 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,689,443,052.49 | 3,080,014,908.83 | 3,039,275,263.67 | 3,018,664,405.93 |
| 资产总计 | 38,663,681,854.02 | 36,329,170,467.82 | 35,504,476,261.22 | 31,430,405,810.37 |
| 流动负债: | | | | |
| 流动负债合计 | 24,261,850,974.74 | 22,900,519,254.91 | 22,430,972,576.41 | 18,520,454,694.33 |
| 非流动负债: | | | | |
| 非流动负债合计 | 5,643,146,349.75 | 5,124,976,978.48 | 4,610,137,631.04 | 4,657,060,749.56 |
| 负债合计 | 29,904,997,324.49 | 28,025,496,233.39 | 27,041,110,207.45 | 23,177,515,443.89 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,258,288,291.66 | 7,254,907,215.26 | 7,357,581,482.86 | 7,185,054,665.95 |
| 股东权益合计 | 8,758,684,529.53 | 8,303,674,234.43 | 8,463,366,053.77 | 8,252,890,366.48 |
| 负债和股东权益合计 | 38,663,681,854.02 | 36,329,170,467.82 | 35,504,476,261.22 | 31,430,405,810.37 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 36,084,011,135.33 | 23,648,603,036.98 | 10,503,310,948.63 | 55,660,431,363.06 |
| 经营活动现金流出小计 | 42,646,442,774.92 | 28,808,381,959.37 | 15,697,812,024 | 55,568,622,434.11 |
| 经营活动产生的现金流量净额 | -6,562,431,639.59 | -5,159,778,922.39 | -5,194,501,075.37 | 91,808,928.95 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 567,858,965.25 | 419,724,626.05 | 219,777,243.86 | 1,524,569,422.27 |
| 投资活动现金流出小计 | 1,050,361,320.32 | 436,522,279.45 | 257,208,401.67 | 1,720,274,104.16 |
| 投资活动产生的现金流量净额 | -482,502,355.07 | -16,797,653.4 | -37,431,157.81 | -195,704,681.89 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 22,914,160,450.35 | 18,566,246,206.2 | 9,123,845,116.03 | 22,151,533,261.66 |
| 筹资活动现金流出小计 | 16,999,727,903.69 | 13,655,121,733.28 | 5,025,672,719.14 | 22,582,463,807.62 |
| 筹资活动产生的现金流量净额 | 5,914,432,546.66 | 4,911,124,472.92 | 4,098,172,396.89 | -430,930,545.96 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | -1,130,501,448 | -265,452,102.87 | -1,133,759,836.29 | -534,826,298.9 |
| 期末现金及现金等价物余额 | 1,262,808,709.65 | 2,127,858,054.78 | 1,259,550,321.36 | 2,393,310,157.65 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -265,452,102.87 | - | -534,826,298.9 |